Association between serum cystatin C and diabetic peripheral neuropathy: A cross-sectional study of a Chinese type 2 diabetic population

European Journal of Endocrinology

Volumn 171, Issue 5, 2014, Pages 641-648

  Hu, Yanyun ^a,b   Liu, Fang ^a,b   Shen, Jing ^a,b   Zeng, Hui ^a   Li, Lianxi ^a,b   Zhao, Jun ^c   Zhao, Jungong ^a   Lu, Fengdi ^a   Jia, Weiping ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b Shanghai Clinical Center of Diabetes   (China)

^c Department of Vascular Surgery ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; CYSTATIN C; HEMOGLOBIN A1C; BIOLOGICAL MARKER; CST3 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE MARKER; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; AGED; BLOOD; CHINA; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; EPIDEMIOLOGY; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; CHINA; CROSS-SECTIONAL STUDIES; CYSTATIN C; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 84910121295     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0381     Document Type: Article

References (28)

1. Icks A, Haastert B, Trautner C, Giani G, Glaeske G & Hoffmann F. Incidence of lower-limb amputations in the diabetic compared to the non-diabetic population. findings from nationwide insurance data, Germany, 2005-2007. Expereimental and Clinical Endocrinology & Diabetes 2009 117 500-504. (doi:10.1055/s-0029-1225333)
2. Tesfaye S, Chaturvedi N, Eaton SE, Ward JD, Manes C, Ionescu-Tirgoviste C, Witte DR, Fuller JH & EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. New England Journal of Medicine 2005 352 341-350. (doi:10.1056/NEJMoa032782)
3. Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O'Brien PC, Melton LJ III & Service FJ. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993 43 817-824. (doi:10.1212/WNL.43.4.817)
4. Kärvestedt L, Mårtensson E, Grill V, Elofsson S, von Wendt G, Hamsten A & Brismar K. Peripheral sensory neuropathy associates with micro- or macroangiopathy. Diabetes Care 2009 32 317-322. (doi:10.2337/dc08-1250)
5. Bell DS, Ketchum CH, Robinson CA, Wagenknecht LE & Williams BT. Microalbuminuria Associated With Diabetic Neuropathy. Diabetes Care 1992 15 528-531. (doi:10.2337/diacare.15.4.528)
6. Tangri N, Stevens LA, Schmid CH, Zhang YL, Beck GJ, Greene T, Coresh J & Levey AS. Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney International 2011 79 471-477. (doi:10.1038/ki.2010.431)
7. Dharnidharka VR, Kwon C & Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. American Journal of Kidney Diseases 2002 40 221-226. (doi:10.1053/ajkd.2002.34487)
8. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS & Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. New England Journal of Medicine 2005 352 2049-2060. (doi:10.1056/NEJMoa043161)
9. Ix JH, Shlipak MG, ChertowGM& Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007 115 173-179. (doi:10.1161/CIRCULATIONAHA.106.644286)
10. Deng A, Irizarry MC, Nitsch RM, Growdon JH & Rebeck GW. Elevation of cystatin C in susceptible neurons in alzheimer's disease. American Journal of Pathology 2001 159 1061-1068. (doi:10.1016/S0002-9440(10)61781-6)
11. Nakashima I, Fujinoki M, Fujihara K, Kawamura T, Nishimura T, Nakamura M& Itoyama Y. Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Annals of Neurology 2007 62 197-200. (doi:10.1002/ana.20955)
12. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM et al . Cystatin C inhibits amyloidb deposition in Alzheimer's disease mouse models. Nature Genetics 2007 39 1440-1442. (doi:10.1038/ng.2007.29)
13. Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC & MalorniW. Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. FEBS Letters 2005 579 2759-2766. (doi:10.1016/j.febslet.2005.03.094)
14. Yang Y, Liu S, Qin Z, Cui Y, Qin Y & Bai S. Alteration of cystatin C levels in cerebrospinal fluid of patients with Guillain-Barré Syndrome by a proteomical approach. Molecular Biology Reports 2009 36 677-682. (doi:10.1007/s11033-008-9228-1)
15. Liu F, Shen J, Zhao J, Zeng H, Li L, Zhao J, Lu F, Bao Y & Jia W. Cystatin C: a strong marker for lower limb ischemia in Chinese type 2 diabetic patients? PLoS One 2013 8 e66907. (doi:10.1371/journal.pone. 0066907)
16. He R, Shen J, Zhao J, Zeng H, Li L, Zhao J, Liu F & Jia W. High cystatin C levels predict severe retinopathy in type 2 diabetes patients. European Journal of Epidemiology 2013 28 775-778. (doi:10.1007/s10654-013-9839-2)
17. American Diabetes Association Standards of medical care in diabetes - 2014. Diabetes Care 2014 37 (Suppl 1) S14-S80. (doi:10.2337/dc14-S014)
18. Martin CL, Albers JW, Pop-Busui R & DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014 37 31-38. (doi:10.2337/dc13-2114)
19. Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I & IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. Clinical Chemistry and Laboratory Medicine 2010 48 1619-1621. (doi:10.1515/CCLM.2010.318)
20. Bril V & Perkins BA. Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy. Diabetes Care 2002 25 2048-2052. (doi:10.2337/diacare.25.11.2048)
21. Apelqvist J, Bakker K, van Houtum WH, Schaper NC & International Working Group on the Diabetic Foot (IWGDF) Editorial Board. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) prepared by the international working group on the diabetic foot. Diabetes/Metabolism Research and Reviews 2008 24 (Suppl 1) S181-S187. (doi:10.1002/dmrr.848)
22. Shen J, Hu Y, Liu F, Zeng H, Li L, Zhao J, Zhao J, Zheng T, Lu H, Lu F et al. Vibration perception threshold for sight-threatening retinopathy screening in type 2 diabetic outpatients. Diabetes/Metabolism Research and Reviews 2013 29 525-531. (doi:10.1002/dmrr.2423)
23. Xiaofu T. Clinical eceltromyography study. Beijing: The Beijing University of Science and Technology China harmony Medical college unites the publishing house, 1995. pp 51-60.
24. Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S & Herrmann M. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999 30 1190-1195. (doi:10.1161/01.STR.30.6.1190)
25. Deng A, Irizarry MC, Nitsch RM, Growdon JH & Rebeck GW. Elevation of cystatin C in susceptible neurons in Alzheimer's disease. American Journal of Pathology 2001 159 1061-1068. (doi:10.1016/S0002-9440(10)61781-6)
26. MussapM, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R & Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney International 2002 61 1453-1461. (doi:10.1046/j.1523-1755.2002.00253.x)
27. Tangri N, Stevens LA, Schmid CH, Zhang YL, Beck GJ, Greene T, Coresh J & Levey AS. Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. Kidney International 2011 79 471-477. (doi:10.1038/ki.2010.431)
28. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC & de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International 2004 65 1416-1421. (doi:10.1111/j.1523-1755.2004.00517.x)